Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to mark and kill only cancer cells. Antibody drug conjugates are compound molecules that comprise antibodies linked to a biologically active cytotoxic drug.
By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost growth of the global antibody drug conjugates market.

Request Sample of Antibody Drug Conjugates Market:https://www.coherentmarketinsights.com/insight/request-sample/181

Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to over US$ 10 billion over the forecast period of market
In terms of marketing, three antibody drug conjugates have received regulatory approval.  The U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins.

Antibody drug conjugates market is still in its infancy, with two approved ADCs to propel the market to two digit billion dollar mark by 2020
The global antibody drug conjugates market is segmented on the basis of drug and geography. On the basis of drug, the market is divided into Adcetris and Kadcyla.
Major pharmaceutical company opt for contract manufacturer for development and manufacture of antibody drug conjugates
Regional segmentation of the antibody drug conjugates market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Europe accounts for the largest share in the global market mainly due to presence of many contract manufacturing companies with advanced manufacturing equipment. Lonza is one of the top contract manufacturing companies in Europe, which has operations across France and Germany, with its headquarters in Switzerland. One of the facilities operated by the company is a deck to chemical manufacturing capabilities and develop peptides, small molecule active pharmaceutical ingredients, highly potent active pharmaceutical ingredients, cytotoxics agents, antibody drug conjugates, and microbial products. The company also offer proficiency in chemical, pharmaceutical, agrochemical and food industries by providing clients with yields such as high-class active substances, organic chemicals and intermediates.

Large number of clinical trial molecules in pipeline to boost growth of antibody drug conjugates market
Key players operating the antibody drug conjugates market include Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals. Major companies in the antibody drug conjugates industry are constantly working on research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, there are only two antibody drug conjugates available worldwide that are used to treat cancer, and there are over 40 molecules under clinical trials. Considering the alarmingly high incidence rate of cancer across the globe, the antibody conjugates market is expected to ride on a wave of positive growth in the foreseeable future.

Check The Trending Report of Antibody Drug Conjugates Market:https://www.coherentmarketinsights.com/ongoing-insight/antibody-drug-conjugates-market-181

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.